From the FDA Drug Label
2.3 Dosage for Treatment of ADHD The recommended starting dosage in adults and pediatric patients 6 years and older is 30 mg once daily in the morning. Dosage may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals up to maximum recommended dosage of 70 mg once daily 2.4 Dosage for Treatment of Moderate to Severe BED in Adults The recommended starting dosage in adults is 30 mg once daily to be titrated in increments of 20 mg at approximately weekly intervals to achieve the recommended target dose of 50 mg to 70 mg once daily. The maximum recommended dosage is 70 mg once daily
The dose of Vyvanse (lisdexamfetamine) is:
- 30 mg once daily as the recommended starting dosage for ADHD in adults and pediatric patients 6 years and older
- 30 mg once daily as the recommended starting dosage for moderate to severe BED in adults, with a target dose of 50 mg to 70 mg once daily
- Maximum recommended dosage is 70 mg once daily for both ADHD and BED 1
From the Research
Dose of Vyvanse (Lisdexamfetamine)
- The dose of Vyvanse (lisdexamfetamine) varies depending on the condition being treated and the patient population 2, 3, 4, 5.
- For attention-deficit/hyperactivity disorder (ADHD), the dose of lisdexamfetamine is typically in the range of 30-70 mg/day 4, 5.
- In clinical studies, lisdexamfetamine has been shown to be effective in reducing symptoms of ADHD at doses of 30-70 mg/day 4, 5.
- For binge eating disorder, the approved dose of lisdexamfetamine is 50-70 mg/day 3.
- The pharmacokinetics of lisdexamfetamine have been studied in healthy adult volunteers, with a dose of 70 mg/day resulting in a mean steady-state concentration of d-amphetamine of 20.6 ng/mL 6.
Key Findings
- Lisdexamfetamine is a prodrug that is converted to its active form, d-amphetamine, in the blood following oral administration 2, 4.
- The efficacy and safety of lisdexamfetamine have been demonstrated in several clinical studies in patients with ADHD and binge eating disorder 2, 3, 4, 5.
- Lisdexamfetamine has a unique pharmacokinetic profile that allows for once-daily dosing and a duration of activity of approximately 12 hours 4, 6.